Street Calls of the Week
Investing.com -- Telomir Pharmaceuticals (NASDAQ:TELO) stock surged 21.2% on Thursday after the company announced promising laboratory results for its lead drug candidate against triple-negative breast cancer (TNBC), one of the most aggressive and difficult-to-treat forms of the disease.
The preclinical-stage biotechnology company reported that Telomir-1 demonstrated a dose-dependent reduction in cancer cell survival in human TNBC cells. Researchers found that adding iron back to the system reversed the effect, confirming the drug’s mechanism involves regulation of cellular iron and energy balance.
This discovery is particularly significant because aggressive cancer cells like those in TNBC are highly dependent on iron to support their rapid growth. By disrupting this iron-driven process, Telomir-1 appears to target a metabolic vulnerability specific to cancer cells while potentially sparing healthy tissue.
The company noted that Telomir-1 has previously shown ability to reset abnormal DNA methylation patterns and restore balanced gene expression in models of cancer and age-related disease. The new findings suggest the drug may influence epigenetic mechanisms that control iron use, oxidative stress, and energy metabolism.
Triple-negative breast cancer accounts for approximately 10-15% of all breast cancer cases but has limited treatment options because it lacks the hormone and HER2 receptors that can be targeted by existing therapies. Current treatments primarily include chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates.
Telomir plans to expand testing to additional cancer types, including pancreatic cancer and leukemia models, and conduct further animal studies as it prepares for an Investigational New Drug submission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.